Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Transdel Pharmaceuticals, a specialty pharmaceutical company developing non-invasive, topically delivered medications, has retained FLP Pharma, a Georgia-based pharmaceutical consultancy, to lead its business development activities, especially the out-licensing of its lead product Ketotransdel.
Subscribe to our email newsletter
The company said that it is also investigating other novel and generic drugs and promising therapeutic areas in combination with using its patented transdermal delivery system.
Juliet Singh, president and CEO of Transdel, said: “Our Phase III clinical trial of Ketotransdel continues to advance. We also continue to explore co-development opportunities in other therapeutic areas utilizing our Transdel platform technology.
“With the addition of FLP Pharma and its successful track record, we expect to significantly advance our partnering efforts especially for our lead pain product Ketotransdel and achieve a significant milestone in our growth as a specialty pharmaceutical company.”